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Abstract
In Hypertrophic Obstructive Cardiomyopathy Associated to Sigmoid Septum (HOCM/SS), the left ventricular outflow tract obstruction is a 
complex dynamic phenomenon where the asymmetric hypertrophy of the basal septum and associated anomalies of the mitral valve leaflets and 
subvalvular apparatus are less likely to explain per se the subaortic obstruction. It is our view that the closure of the aorto-mitral angle in this setting 
is paramount. It entails, for obvious geometric reasons, a bulging of the basal septum underneath the aortic valve and the misalignment between 
the LV and outflow/aortic root creates the path for an ejectional flow pattern, which may drag the mitral apparatus and promote obstruction by 
pushing the subvalvular apparatus and leaflets in the outflow tract. Via the presentation of a complex HOCM/SS case, the pertinent recent literature 
on this subject is summarized and the recommendations for interventional treatment are discussed. Even with close results, surgery appears to be 
more efficient in this setting.
Abbreviations 
ACCF: American College of Cardiology Foundation; AHA: American Heart Association; AVB: Atrioventricular Block; ED: Emergency 
Department; ESC: European Society of Cardiology; HCM: Hypertrophic Cardiomyopathy; HOCM: Hypertrophic Obstructive Cardiomyopathy; 
HOCM/SS: Hypertrophic Obstructive Cardiomyopathy associated to Sigmoid Septum; LV: Left Ventricle; LVOT: Left Ventricular Outflow Tract; 
MR: Mitral Regurgitation; SAM: Systolic Anterior Motion of mitral valve; SS: Sigmoid Septum
Introduction
Hypertrophic Cardiomyopathy (HCM) is a heterogeneous clinical 
entity whose etiology is most of the time genetic. HCM is characterized 
by left ventricular wall hypertrophy not explained by the loading 
conditions (e.g., systemic hypertension, aortic valve stenosis) [1]. This 
pathology represents the most common cause of sudden cardiac 
death among young adults, as well as a significant part of heart failure 
cases. Amongst the elderly, the hypertrophic myocardium is mostly 
localized at the base of the interventricular septum and associated 
changes in local geometry gives a typical morphologynamed Sigmoid 
Septum (SS) [2].
We report the case of a patient with hypertrophy of the basal 
interventricular septum associated to a Systolic Anterior Motion of the 
mitral valve (SAM). 
Clinical case
The patient is a 65 years old Caucasian male. He was admitted in 
the Emergency Department (ED) in February 2013 after a syncope 
preceded by rapid palpitations during a moderate effort. His medical 
records revealed that he was followed at the cardiology clinic for a 
non-obstructive septal hypertrophy diagnosed 2 years before. He was 
on chronic therapy with bisoprolol 5mg/day. Rest echocardiography 
showed thickening of the LV basal septum of 18 mm, a SAM causing 
a subaortic peak gradient of 135 mmHg at rest and a moderate 
secondary Mitral Regurgitation (MR). Syncope was considered to be 
at least partially related to the dynamic subaortic gradient. Therefore, 
verapamil 240 mg was added to 2.5 mg bisoprololallowing a reduction 
of the subaortic peak gradient from 135 to 32 mmHg at rest.
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Two weeks later, despite treatment adjustment, syncope relapsed. 
An automated internal defibrillator was implanted, as the patient was 
considered at high risk of malignant arrhythmias. The new treatment 
with sotalol 80 mg and verapamil 240 mg allowed a reduction of the 
gradient to 30 mmHg at rest but still at 72 mmHg during the Valsalva 
manoeuvre. 
His clinical condition remained stable until March 2015when he 
presented several episodes of true syncope. The subaortic gradient 
was as high as 125 mmHg at rest (Figure 1). Given the recurrence 
of symptoms despite optimal treatment, alcohol septal ablation was 
proposed to relieve the obstruction. Transthoracic echocardiogram 
with intracoronary contrast was used to assess the suitability of a first 
septal perforator for this procedure. The intervention was conducted 
without complications and a part of the basal septum necrotized 
(max. CK-MB 163 µg/L) after injection of 2 mL of pure ethanol. 
The echocardiographic control revealed a reduction in the subaortic 
gradient at 54 mmHg at rest. However, the SAM persisted and the 
peak subaortic gradient during Valsalva was still as high as 130 mmHg 
with moderate secondary MR. Furthermore, despite focal mid-septal 
thinning, the basal septum remained at 18 mm (Figure 2). 
Until July 2015, his clinical status did not improve with recurrent 
syncope complicated by head trauma that resulted in subarachnoid 
hemorrhage. Given the lack of improvement, a septal myectomy was 
indicated.
The intervention was performed in September 2015 under 
extracorporeal circulation. After aortic cross clamping, a transverse 
aortotomy allowed visualization of the underlying basal septal bulge 
through a non-calcified and competent aortic valve. A wide, but 
relatively shallow (8 mm) septal myotomy and myectomy (Morrow 
procedure) was performed to relieve LVOT obstruction. 
Surgery and the postoperative course were uneventful. Rest 
echocardiography two weeks after the intervention showed absence of 
subaortic gradient at rest and after Valsalva manoeuvre and the absence 
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of SAM, and therefore complete disappearance of the secondary MR 
(Figure 3). At follow-up, the patient did not report any syncopenor any 
other symptoms related to his pathology.
Discussion 
Septal bulging protruding into the LVOT is not an uncommon 
echocardiographic finding in elderly patients. It has long been 
acknowledged that the senescent heart undergoes morphological 
modifications among which the dilation and the rightward shift of the 
ascending aorta and the decrease in long-axis dimension of the left 
ventricular cavity [3]. These geometrical modifications will both cause 
a leftward shift of the septum giving a sigmoid shape and closing the 
aorto-mitral angle (Figure 4-D). In elderly patients, this angulation may 
or may not be associated to basal septal hypertrophy [4]. Therefore, 
these morphological changes can be observed in the symptom free 
elderly subjects [2,5].
The prevalence of SS in the general population is estimated between 
5,8% and 7% and considerably increases with age: 1,7% < 57 years old 
and 16,7%> 78 years old [5,6]. The sex ratio seems identical in the 
different age groups with a 1:1 distribution [5,6].
Its etiology is still a matter of discussion. Several authors consider 
SS as a true form of HCM. Others consider it as an anatomic variant 
whose prevalence rises with age-related conditions such as increased 
impedance to flow during ejection and dilation/elongation of root 
vessels [4,5]. Spirito et al., [6] tend to class the SS within primary HCM 
because it shares common features of HCM (e.g. diastolic dysfunction). 
In a more recent study, Bos et al., [7] reported the absence of genetic 
mutation but the presence of this septal bulging in the majority of the 
patients diagnosed with HCM after the age of 65. They concluded that 
most of the patients with a late diagnosis are likely to have an acquired, 
non-genetic subtype of HCM rather than the inherited type. This 
particular presentation of hypertrophy could also be caused by other 
unidentified mutations with late penetrance.
Meanwhile, if the cause of the SS is still debated there is no doubt 
that this subtype of hypertrophy can lead to the obstruction of the 
LVOT through a physiopathological mechanism similar to that found 
in the primary Hypertrophic Obstructive Cardiomyopathy (HOCM) 
but where closure of the aorto-mitral angle and related modifications 
on LV flow pattern are likely to play a preponderant role [8].
Physiopathology
The LVOT obstruction, defined by an intraventricular gradient 
≥ 30 mmHg [9], is a complex and multifactorial phenomenon. Its 
prevalence into the HCM population is estimated at 20-30% at rest and 
reaches almost 40% during exercise [10]. In some genetic HOCM, the 
obstruction occurs at the mid-ventricular level where the hypertrophied 
septum touches the anterior papillary muscle [10]. However, in most 
cases, the obstruction is due to the narrowing of the LVOT caused by 
the bulging of the hypertrophied basal septum inside the LVOT. This 
could be the consequence of pure myocardial hypertrophy as found in 
HCM forms of young people or mild/moderate hypertrophy associated 
to an age-related angulation of the aorto-septal junction defining the 
SS. Several mechanisms may contribute to the SAM; they are not 
mutually exclusive.
First the pushing force of flow, called “flow drag” which is probably 
the predominant mechanism [11], catches the mitral leaflets during 
ejection and pushes them in the LVOT [12]. Indeed, under physiological 
conditions the left ventricular systolic flow crosses the ventricle and 
outflow tract without encountering the mitral valve apparatus owing 
to the remote postero-lateral coaptation of the mitral leaflets (Figure 
4-A&B). This accounts for a lack of interference between the inflow 
and outflow components of the left ventricular chamber. In HOCM 
conditions, the septal bulge induces a curvilinear intraventricular 
flow pattern which may encounter the mitral valvular and subvalvular 
apparatus especially if anomalies (aberrant cordae, longer mitral valve 
leaflets, etc.), frequently found in HCM,are present (Figure 4-C).In this 
situation the pushing force of the flow will bring the anterior mitral 







Dulgheru R, et al. GSL Cardiovasc Dis. 2018; 1:105 | Volume 1, Issue 1
Citation: Walhin N, Dulgheru R, Bonnet P, Petitjean H, Radermecker A, et al. HOCM/Sigmoid septum: mechanism and management of the 
obstruction. GSL Cardiovasc Dis. 2018; 1:105.
leaflet in contact with the interventricular septum [12]. Accordingly, in 
HOCM/SS the isolated closure of the aorto-mitral angle can promote 
on its own this effect of flow drag (Figure 4-D).
Second, the Bernoulli derived flow acceleration at the level of the 
LVOT narrowing, decreases locally the side-pressure and “aspirates” 
the mitral leaflet through a Venturi effect [13].
Third, the fibrosis of both fibrous trigones described in HCM has 
been invoked by Yacoub et al., [14]. Physiologically these trigones 
have a speculative “hinge” function during systole and allow maximal 
widening of LVOT through the backward displacement of the subaortic 
curtain and the anterior leaflet of the mitral valve. The reduction of 
this “hinge mechanism” may contribute to a reduction of the LVOT 
surface area and width during systole [14]. This fibrosis of the trigones 
is present in elderly even in absence of HCM condition [15].
These three mechanisms, intermingled at varying degrees, generate 
the dynamic phenomenon of sub-aortic obstruction and contribute to 
the development of secondary mitral insufficiency by decreasing the 
efficiency of leaflets coaptation. 
Symptoms and diagnosis
The SS may evolve insidiously and can be diagnosed incidentally 
in asymptomatic patients [2,5]. In obstructive forms, the patient may 
develop various symptoms as found in classical HOCM [16].
Exertional dyspnea may appear gradually. It is explained by the 
associations of diastolic dysfunction and secondary dynamic MR 
related to SAM, reverberating upstream by pulmonary venous network 
congestion. 
Nearly one in two patients’ develops angina. This is due to increased 
cardiac work plus microcirculation anomalies exacerbated in genetic 
forms [10].
Less frequently, patients report fainting or syncopal events 
provoked by intense exercise. These may be due to the occurrence of 
reflex bradycardia associated with a peripheral vasodilation known as 
Bezold-Jarisch reflex [17]. This vagal event occurs when the pressure 
developed in the LV is abnormally high and results in transient low 
cardiac output. Malignant ventricular arrhythmia should also be 
suspected in patients with syncope or fainting. 
The SS is defined as an isolated myocardial hypertrophy localized 
at the proximal third of the interventricular septum and bulging 
into the LVOT with thickness ≥ 13 mm among males and ≥ 12 mm 
among females and exceeding of over 50% the septal thickness at mid-
ventricular level [5]. Once abnormal basal septal geometry is revealed 
with transthoracic rest echocardiography, the presence/absence of 
subaortic obstruction at rest as well as during provocative manoeuvres 
(such as Valsalva) should be systematically assessed, since it holds a key 
role in the therapeutic management. 
Early diagnosis of this particular form of HOCM even at an 
asymptomatic stage is important, as progression can affect the quality 
of life. Some surgical teams have also pointed to the importance of 
describing this unusual septal morphology before mitral valve repair 
procedures. Indeed mitral surgery also via closure of the aorto mitral 
angle can herald sub-valvular obstruction and SAM (Figure4-E) 
[18,19]. 
Management of HOCM/SS
Usually the above-mentioned symptoms begin to manifest with 
a gradient superior to 50 mmHg. The initial management of these 
symptoms will be through medical treatment. If the symptoms become 
unrelenting and refractory to medications, invasive treatment will be 
considered. 
When the HOCM/SS becomes obstructive and refractory to the 
drug therapy, (in the absence of specific guidelines for this particular 
subset), the treatment is based on the HOCM guidelines. In our 
opinion a case-by-case assessment is necessary considering the absence 
of obvious septal hypertrophy in some cases (Figure 5).
The latest European guidelines published by the European Society of 
Cardiology (ESC) [20] and the American guidelines published jointly 
by the American College of Cardiology Foundation (ACCF) and the 
American Heart Association (AHA) [21] for the use of these different 
treatments can be summarized as follows.
Drug treatment
ESC and ACCF/AHA agree that treatment should be started with 
a cardio-selective β-blocker upto the maximum tolerated dose. In 
case of contraindications, Verapamil is an alternative or will be added 
β-blockers for more efficacy. If symptoms are not adequately controlled 
by this association, it is recommended to combine the disopyramide to 
one of these two drugs. 
Invasive treatment
Septal reduction is recommended (myectomy or alcohol ablation) 
in any patients with an intraventricular gradient ≥50 mmHg and severe 
symptoms refractory to an optimal drug therapy. However, as regards 




Dulgheru R, et al. GSL Cardiovasc Dis. 2018; 1:105 | Volume 1, Issue 1
Citation: Walhin N, Dulgheru R, Bonnet P, Petitjean H, Radermecker A, et al. HOCM/Sigmoid septum: mechanism and management of the 
obstruction. GSL Cardiovasc Dis. 2018; 1:105.
Association Scientific Statement from the Council on Clinical 
Cardiology, Heart Failure and Transplantation Committee; 
Quality of Care and Outcomes Research and Functional Genomics 
and Translational Biology Interdisciplinary Working Groups; and 
Council on Epidemiology and Prevention. Circulation, 113: 1807-
1816.
2. Goor D, Lillehei CW, Edwards JE, 1969 The “sigmoid septum”. 
Variation in the contour of the left ventricular outt. Am J 
Roentgenol Radium Ther Nucl Med, 107: 366-376.
3. Waller BF, 1988 The old-age heart: normal aging changes which 
can produce or mimic cardiac disease. Clin Cardiol, 11: 513-517.
4. Krasnow N, 1997 Subaortic septal bulge simulates hypertrophic 
cardiomyopathy by angulation of the septum with age, 
independent of focal hypertrophy. An echocardiographic study. 
J Am Soc Echocardiogr, 10: 545-55. 
5. Canepa M, Malti O, David M, 2014 Prevalence, clinical correlates, 
and functional impact of subaortic ventricular septal bulge (from 
the Baltimore Longitudinal Study of Aging). Am J Cardiol, 114: 
796-802.
6. Ranasinghe I, Ayoub C, Cheruvu C, 2014 Isolated hypertrophy 
of the basal ventricular septum: characteristics of patients with 
and without outflow tract obstruction. Int J Cardiol, 173: 487-493.
7. Spirito P, Maron BJ, Bonow RO, 1986 Severe functional limitation 
in patients with hypertrophic cardiomyopathy and only mild 
localized left ventricular hypertrophy. J Am Coll Cardiol, 8: 537-
544. 
8. Bos JM, Will M, Ommen S, 2013 Yield of genetic testing among 
patients with hypertrophic cardiomyopathy diagnosed after 65 
years of age. J Am Coll Cardiol, 61: E1305.
9. Maron MS, Olivotto I, Betocchi S, 2003 Effect of left ventricular 
outflow tract obstruction on clinical outcome in hypertrophic 
cardiomyopathy. N Engl J Med, 348: 295-303.
10. Olivotto I, Girolami F, Nistri S, 2009 The many faces of 
hypertrophic cardiomyopathy: from developmental biology to 
clinical practice. J Cardiovasc Transl Res, 2: 349-367.
11. Sherrid MV, Gunsburg DZ, Moldenhauer S, 2000 Systolic anterior 
motion begins at low left ventricular outflow tract velocity in 
obstructive hypertrophiccardiomyopathy. J Am Coll Cardiol, 36: 
1344-1354.
12. Maron BJ, 2002 Hypertrophic cardiomyopathy: a systematic 
review. JAMA, 287: 1308-1320. 
13. Sherrid MV, Chu CK, Delia E, 1993 An echocardiographic 
study of the fluid mechanics of obstruction in hypertrophic 
cardiomyopathy. J Am Coll Cardiol, 22: 816-825.
14. Yacoub M, Onuzo O, Riedel B, 1999 Mobilization of the left and 
right fibrous trigones for relief of severe left ventricular outflow 
obstruction. J Thorac Cardiovasc Surg, 117: 126-133.
15. Tohno S, Azuma C, Tohno Y, 2007. Increases of calcium, 
phosphorus, and magnesium in both the right and left fibrous 
trigones of human heart with aging. Biol Trace Elem Res, 119: 
111-119.
16. Stevenson LW, Loscalzo J, 2013 Cardiomyopathies et myocardites, 
in Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, 
Loscalzo J Ed., Harrison Principes de Médecine Interne. Dix-
huitième édition. Lavoisier, Paris, 1951-1970.
to the procedure of choice, there are some discrepancies between the 
American and European guidelines. 
Surgery is proposedas a first-line (IIa recommendation) according 
to the ACCF/AHA. The success of the surgical technique is estimated 
at 90-95% whereas it is slightly lower after alcohol ablation for 
an estimated morbidity and mortality less than 1% and up to 4% 
respectively. The invasiveness of heart surgery is counter balanced by 
lighter interventional techniques. 
The recommendations of the ESC are less in favour of the surgical 
procedure excepted when magnetic resonance reveals a wide septal 
fibrosis or for hypertrophied septum greater than 30 mm. The ESC 
guidelines mention that the overall success rate (about 90%) in terms 
of improved effort capacity and mortality is quite similar between the 
two techniques. Therefore, the selection of the procedure should be 
determined by a multidisciplinary team that will also take into account 
the operators’ experience. 
The lack of consensus between these two guidelines led us to review 
morbidity and mortality data from the literature. Unfortunately, level I 
recommendation will probably never take place [22].
Sorajja et al., [23] compared the two procedures at four years in 
terms of survival and sustained improvement of symptoms.The results 
were quite similar in both age and gender comparable populations. 
However, complete Atrioventricular Block (AVB) rate requiring 
definitive pacemaker implantation (20%) was 4 times higher following 
alcohol ablation than after myectomy. Long-term survival was similar 
to the general population with nevertheless significantly higher post 
procedure gradients after percutaneous ablation [24]. 
Several meta-analyses have demonstrated similar efficacy for both 
procedures, as much with clinical and echographic improvement with 
falling of subaortic gradient, as by low mortality rate less than 1 to 2% 
[25-27]. However, the residual gradient remained significantly higher 
after septal ablation (15-18 mmHg vs. 9-10 mmHg) as the need to 
implant permanent pacemaker (18-20,9% vs. 3,4-4,4%).
Of note is that surgical myectomy after an ineffective alcohol 
ablation, is at higher risk of dysrhythmic complications requiring the 
implantation of permanent pacemaker in 50% to 85% of the patients 
[21,28,29]. Moreover, the risk of heart failure and postoperative 
mortality is also higher than in a first-line myectomy [25]. 
Conclusions
The HOCM/SS is a real clinical entity and quite frequent 
in the elderly. While the etiology is imperfectly elucidated, the 
pathophysiology is well explained by the misalignment of the aortic 
root associated or not with septal bulging and inducing the closure 
of the aorto-mitral angle. The echocardiographic identification and 
follow-up of these patients is important. Indeed, this misalignment 
may worsen over time as presented here and may cause HOCM 
symptoms requiring therapeutic support up to septal reduction. It 
has also surgical implications, as after mitral valve repair with ring 
annuloplasty, precipitating the LVOT obstruction while the gradient 
was beforehand non-significant. 
Current procedures of septal reduction (i.e. septal alcohol ablation 
and septal myectomy) which are efficient in the classic genetic HOCM 
are also relevant for HOCM/SS. However, myectomy seems to us 
more appropriate in this pathology mainly localised at the level of the 
basal septum. The resection the septal bulge is easy in this setting and 
completely corrects both LVOT obstruction and SAM.
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